We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-7.93%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$973M
AUM Growth
-$259M
Cap. Flow
-$139M
Cap. Flow %
-14.32%
Top 10 Hldgs %
31.9%
Holding
97
New
2
Increased
29
Reduced
54
Closed
5

Top Buys

Rank Stock Value
1
ZBH icon
Zimmer Biomet
ZBH
+$13.3M
2
CI icon
Cigna
CI
+$11.7M
3
BIIB icon
Biogen
BIIB
+$9.55M
4
HUM icon
Humana
HUM
+$6.5M
5
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$6.19M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$15.7M
2
BDX icon
Becton Dickinson
BDX
+$14.9M
3
HCA icon
HCA Healthcare
HCA
+$14.6M
4
BSX icon
Boston Scientific
BSX
+$12.9M
5
COO icon
Cooper Companies
COO
+$11.5M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BSX icon
1
Boston Scientific
BSX
$69.5B
$39.7M 4.08%
444,000
-146,000
-25% -$12.9M
LLY icon
2
Eli Lilly
LLY
$1.02T
$35.1M 3.61%
45,450
-2,050
-4% -$1.7M
PRCT icon
3
Procept Biorobotics
PRCT
$1.06B
$33.8M 3.48%
420,345
-24,655
-6% -$2.11M
ISRG icon
4
Intuitive Surgical
ISRG
$127B
$33.4M 3.43%
64,000
+1,000
+2% +$521K
REGN icon
5
Regeneron Pharmaceuticals
REGN
$78.5B
$31M 3.18%
43,457
+4,457
+11% +$3.74M
UNH icon
6
UnitedHealth
UNH
$376B
$30.6M 3.15%
60,530
-12,170
-17% -$6.91M
INSP icon
7
Inspire Medical Systems
INSP
$1.45B
$27.8M 2.86%
150,041
+28,041
+23% +$5.44M
MRK icon
8
Merck
MRK
$322B
$27.6M 2.84%
277,500
+36,500
+15% +$3.76M
EXAS
9
DELISTED
Exact Sciences
EXAS
$26.5M 2.72%
471,000
+6,000
+1% +$373K
THC icon
10
Tenet Healthcare
THC
$20.5B
$25M 2.57%
197,700
-23,700
-11% -$3.52M
GILD icon
11
Gilead Sciences
GILD
$162B
$23.6M 2.43%
255,500
-111,000
-30% -$9.99M
ABBV icon
12
AbbVie
ABBV
$443B
$22.1M 2.27%
124,150
-52,850
-30% -$9.72M
CI icon
13
Cigna
CI
$73.7B
$21.6M 2.22%
78,385
+36,700
+88% +$11.7M
MDT icon
14
Medtronic
MDT
$109B
$21.5M 2.21%
269,500
-98,500
-27% -$8.53M
VRTX icon
15
Vertex Pharmaceuticals
VRTX
$121B
$20.1M 2.07%
50,000
+2,250
+5% +$1.04M
ALHC icon
16
Alignment Healthcare
ALHC
$3.08B
$19.8M 2.04%
1,761,192
-216,171
-11% -$2.53M
NTRA icon
17
Natera
NTRA
$38.3B
$19.5M 2.01%
123,410
-107,590
-47% -$15.7M
MCK icon
18
McKesson
MCK
$100B
$19.4M 2%
34,117
+4,000
+13% +$2.24M
BIIB icon
19
Biogen
BIIB
$30B
$18.9M 1.94%
123,700
+56,600
+84% +$9.55M
OSCR icon
20
Oscar Health
OSCR
$9.41B
$18.3M 1.88%
1,362,421
-8,726
-0.6% -$140K
JAZZ icon
21
Jazz Pharmaceuticals
JAZZ
$15.9B
$17.9M 1.84%
145,500
+52,500
+56% +$6.19M
BMRN icon
22
BioMarin Pharmaceuticals
BMRN
$11.6B
$16.5M 1.69%
250,623
-113,877
-31% -$7.63M
RPRX icon
23
Royalty Pharma
RPRX
$25.9B
$15.2M 1.56%
595,000
-18,500
-3% -$491K
PODD icon
24
Insulet
PODD
$11.5B
$14.9M 1.53%
57,000
+17,000
+43% +$4.28M
ITCI
25
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$14.7M 1.51%
176,000
-29,500
-14% -$2.42M
1
2 3 4

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2024 Portfolio in Review

As of Q4 2024, Rhenman & Partners Asset Management held 97 positions worth $973M, down 21% from $1.23B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $139M in Q4 2024, closing 5 positions and reducing 54 holdings. Its most notable exit was Evolent Health, an estimated $7.49M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Rhenman & Partners Asset Management opened a new position in Zimmer Biomet worth $13.1M.

  • Rhenman & Partners Asset Management's largest Q4 2024 buy was Zimmer Biomet: 124,000 shares worth $13.1M.
  • Rhenman & Partners Asset Management added most to Cigna in Q4 2024, an estimated $11.7M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2024 reduction was Natera, cutting an estimated $15.7M.
  • Rhenman & Partners Asset Management fully exited Evolent Health in Q4 2024, selling an estimated $7.49M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 32% of its $973M portfolio in Q4 2024.
  • Rhenman & Partners Asset Management opened 2 new positions and closed 5 in Q4 2024.
  • Rhenman & Partners Asset Management's portfolio value fell 21% quarter-over-quarter to $973M.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2024, filed 13 Feb 2025.